Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Medicare's Blinatumomab Decision, CHAARTED Data Published, New Immuno-Oncology Collaborations, and More

August 14th 2015

Researcher Responsible for CLL Breakthroughs Honored by ASH

July 31st 2015

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

Ibrutinib Induces Impressive Response in DLBCL Subtype

July 30th 2015

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

Idelalisib Use Expands With New CLL Indication Pending

July 30th 2015

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.

Gender Disparities and Other DLBCL Developments

July 28th 2015

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

Novel Agents Continue to Transform Lymphoma Treatment

July 27th 2015

Gilles A. Salles, MD, PhD, discussed treatment regimens being developed for follicular lymphoma.

Blinatumomab Effective in Phase II Ph+ ALL Study

July 17th 2015

Monotherapy with blinatumomab has demonstrated promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia.

Managing CML Following a Suboptimal Response

July 15th 2015

PCR Testing and Treatment Decisions in CML

July 15th 2015

Dosing and Toxicities in TKI Therapy for CML

July 15th 2015

MM-398 Priority Review, CPX-351 in AML, CAR T-cell Collaboration, and More

July 2nd 2015

Ibrutinib Expert Ponders Prospects for Novel Combinations in CLL

July 1st 2015

Jennifer A. Woyach, MD, discusses examining the role of BTK inhibition in CLL using murine and cellular models and mechanisms of resistance to BTK inhibitor therapy.

Non-Intensive Treatments for Mantle Cell Lymphoma

June 30th 2015

Treatments for Relapsed Mantle Cell Lymphoma

June 30th 2015

Upfront Treatments for Mantle Cell Lymphoma

June 30th 2015

Treating Relapsed Diffuse Large B-Cell Lymphoma

June 30th 2015

Diffuse Large B-Cell Lymphoma Treatment Regimens

June 30th 2015

Management of Refractory Follicular Lymphoma

June 30th 2015

Stem Cell Transplantation in Follicular Lymphoma

June 30th 2015

Frontline Treatments for Follicular Lymphoma

June 30th 2015